Bristol Myers Squibb (BMY) Gross Profit (2009 - 2026)

Bristol Myers Squibb has disclosed Gross Profit across 18 years of filings, most recently posting $8.1 billion for Q1 2026.

• In Q1 2026, Gross Profit fell 1.22% year-over-year to $8.1 billion; the TTM figure through Mar 2026 stood at $34.2 billion (up 1.76% YoY), while the FY2025 annual figure was $34.3 billion, changed 0.22% from the prior year.
• Gross Profit fell to $8.1 billion in Q1 2026, from $8.4 billion in the prior quarter.
• Over the last five years, Gross Profit for BMY reached as high as $9.2 billion in Q1 2022 and fell as low as $7.5 billion in Q4 2024.
• The 5-year median for Gross Profit is $8.8 billion (2025), against an average of $8.6 billion.
• Annual changes were most pronounced in 2024 — Gross Profit fell 13.77% — and 2025, when it rose 11.62%.
• A 5-year view of Gross Profit shows it stood at $8.8 billion in 2022, then declined by 0.92% to $8.7 billion in 2023, then slipped by 13.77% to $7.5 billion in 2024, then rose by 11.62% to $8.4 billion in 2025, then dropped by 4.01% to $8.1 billion in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $8.1 billion, $8.4 billion, and $8.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.